Recommendation of the President – Skyrizi (risankizumab)
On 2 April 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 43/2026 on the inclusion of the medicinal product Skyrizi (risankizumab) in the reimbursement program B.32, “Treatment of patients with Crohn’s disease (ICD-10: K50)”